Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | PAK4 | O96013 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.60 |
| ▸ | PRKACA | P17612 | 1/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.60 |
| ▸ | LTK | P29376 | 1/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.60 |
| ▸ | CDK8 | P49336 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374201 | 1.00 | GSK3B (0.60) | GSK3BRPS6KA3CHEK1AURKADAPK3 | |
| SCHEMBL11070341 | 0.89 | CDC7 (0.53) | GSK3BRPS6KA3CHEK1AURKADAPK3 | |
| SCHEMBL30980399 | 0.84 | CDK8 (0.65) | GSK3BRPS6KA3CHEK1AURKADAPK3 | |
| SCHEMBL162420 | 0.84 | CDK8 (0.65) | GSK3BRPS6KA3CHEK1AURKADAPK3 | |
| SCHEMBL4405770 | 0.79 | BCL2L1 (0.57) | DYRK1APTPN2MAPTGAAALDH1A1 | |
| SCHEMBL29913871 | 0.79 | BCL2L1 (0.57) | DYRK1APTPN2MAPTGAAALDH1A1 | |
| SCHEMBL13977223 | 0.79 | DYRK1A (0.71) | GSK3BRPS6KA3CHEK1AURKADAPK3 | |
| SCHEMBL2238245 | 0.78 | PTPN2 (0.60) | CDC7DBF4PTPN2MAPTGAA | |
| SCHEMBL8250276 | 0.78 | HDAC1 (0.60) | PTPN2MAPTGAAALDH1A1PKM | |
| SCHEMBL26564672 | 0.78 | CHEK1 (0.65) | GSK3BRPS6KA3CHEK1AURKADAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-10-20 | — | — | US | disclosed |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | BIOGEN MA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | BIOGEN MA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10460879-B2 | Photoelectric conversion element, dye-sensitized solar cell, metal complex dye, dye solution, dye-adsorbed electrode, and method for producing dye-sensitized solar cell | FUJIFILM CORPORATION (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190218204-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190218204-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2019-07-18 | — | — | US | disclosed |
| US-10081619-B2 | Biaryl inhibitors of bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| WO-2004064836-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| EP-1432707-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2004052461-A1 | COMBINATION FOR THE TREATMENT OF ADHD | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004039366-A1 | NICOTINIC ACETYLCHOLINE AGONISTS IN THE TREATMENT OF GLAUCOMA AND RETINAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-1406901-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | GSK3B 86/4885RPS6KA3 399/4885CHEK1 188/4885 |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | ABL1, BTK, LYN | GSK3B 86/4885RPS6KA3 399/4885CHEK1 188/4885 |
| US-10081619-B2 | Biaryl inhibitors of bruton's tyrosine kinase | ABL1, BTK, LYN | GSK3B 86/4885RPS6KA3 399/4885CHEK1 188/4885 |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | GSK3B 2231/4885RPS6KA3 1530/4885CHEK1 4437/4885 |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | GSK3B 837/4885RPS6KA3 1310/4885CHEK1 3309/4885 |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | GSK3B 86/4885RPS6KA3 399/4885CHEK1 188/4885 |
| US-20190218204-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | GSK3B 86/4885RPS6KA3 399/4885CHEK1 188/4885 |
| US-10460879-B2 | Photoelectric conversion element, dye-sensitized solar cell, metal complex dye, dye solution, dye-adsorbed electrode, and method for producing dye-sensitized solar cell | CHRM1, L1CAM, CRY1 | GSK3B 1617/4885RPS6KA3 2147/4885CHEK1 2785/4885 |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | CHRNA7, CHRNA10, SLC18A3 | GSK3B 1527/4885RPS6KA3 4651/4885CHEK1 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.